Abstract:SARS-CoV-2 is the novel coronavirus causing the COVID-19 pandemic. To enter human cells, the receptor-binding domain (RBD) of the S1 subunit of SARS-CoV-2 (SARS-CoV-2-RBD) initially binds to the peptidase domain of angiotensin-converting enzyme 2 receptor (ACE2-PD). Using peptides to inhibit SARS-CoV-2-RBD binding to ACE2 is a potential therapeutic solution for COVID-19. A previous study identified a 23-mer peptide (SBP1) that bound to SARS-CoV-2-RBD with comparable KD to ACE2. We employed computational protein design and molecular dynamics (MD) to design SARS-CoV-2-RBD 25-mer peptide binders (SPB25) with better predicted binding affinity than SBP1. Using residues 21–45 of the α1 helix of ACE2-PD as the template, our strategy is employing Rosetta to enhance SPB25 binding affinity to SARS-CoV-2-RBD and avoid disrupting existing favorable interactions by using residues that have not been reported to form favorable interactions with SARS-CoV-2-RBD as designed positions. Designed peptides with better predicted binding affinities, by Rosetta, than SPB25 were subjected to MD validation. The MD results show that five designed peptides (SPB25F8N, SPB25F8R, SPB25L25R, SPB25F8N/L25R, and SPB25F8R/L25R) have better predicted binding affinities, by the MM-GBSA method, than SPB25 and SBP1. This study developed an approach to design SARS-CoV-2-RBD peptide binders, and these peptides may be promising candidates as potential SARS-CoV-2 inhibitors.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jpcb.0c07890?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jpcb.0c07890</a>.rmsd plots of ACE2, SBP1, SPB25, and designed peptides in complex with SARS-CoV-2-RBD; rmsd plots of ACE2, SBP1, SPB25, and designed peptides in water; binding free energies of ACE2, SBP1, SPB25, and all designed peptides to SARS-CoV-2-RBD, as calculated with Rosetta and the MM-GBSA method; and hydrogen bond occupations of ACE2, SBP1, SPB25, and designed peptide binding to SARS-CoV-2-RBD (<a class="ext-link" href="/doi/suppl/10.1021/acs.jpcb.0c07890/suppl_file/jp0c07890_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

A Rationally Designed Synthetic Antiviral Peptide Binder Targeting the Receptor-Binding Domain of SARS-CoV-2

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

Structurally Modified Bioactive Peptide Inhibits SARS-CoV-2 Lentiviral Particles Expression

Novel Alkynylamide-Based Nonpeptidic Allosteric Inhibitors for SARS-CoV-2 3-Chymotrypsin-like Protease

Synthetic Peptides Outside the Spike Protein Heptad Repeat Regions As Potent Inhibitors of Sars-Associated Coronavirus

A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor

Antiviral drug design based on the opening mechanism of spike glycoprotein in SARS-CoV-2.

Evaluation of the Binding Affinity of Anti-Viral Drugs against Main Protease of SARS-CoV-2 Through a Molecular Docking Study

Bionics Design of Affinity Peptide Inhibitors for SARS-CoV-2 RBD to Block SARS-CoV-2 RBD-ACE2 Interactions

In silico molecular docking of SARS-CoV-2 surface proteins with microbial non-ribosomal peptides: identification of potential drugs

Computational Design of 25-mer Peptide Binders of SARS-CoV-2

Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells

Designing of peptide aptamer targeting the receptor-binding domain of spike protein of SARS-CoV-2: an in silico study

The Study of Antiviral Drugs Targeting SARS-CoV-2 Nucleocapsid and Spike Proteins Through Large-Scale Compound Repurposing.

In Silico Identification and Analysis of Potentially Bioactive Antiviral Phytochemicals against SARS-CoV-2: A Molecular Docking and Dynamics Simulation Approach

Computational Analysis on the ACE2-derived Peptides for Neutralizing the ACE2 Binding to the Spike Protein of SARS-CoV-2

Computational design of SARS-CoV-2 peptide binders with better predicted binding affinities than human ACE2 receptor

A Broad-Spectrum Macrocyclic Peptide Inhibitor of the SARS-CoV-2 Spike Protein

Peptide S4 is an entry inhibitor of SARS-CoV-2 infection

Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease

Peptide inhibitors derived from the nsp7 and nsp8 cofactors of nsp12 targeting different substrate binding sites of nsp12 of the SARS-CoV-2